Most Read

Through a multi-phase collaboration, WuXi will leverage and evaluate Cyclica’s cloud-based proteome Ligand Express screening platform to investigate the off-target profiles of small molecules, apply Cyclica’s novel and

Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to

Under the deal, the partnership will carry out research and development activities for the advancement of mRNA-based flu vaccines. BioNTech co-founder and CEO Dr Ugur Sahin said: “Today’s

Based in Vienna, Austria, Haplogen is a biotechnology company focused on developing therapeutic substances for the treatment and prevention of infection by the common cold virus. The multi-year

Ankylosing spondylitis is a painful and progressive type of arthritis, in which some or all of the joints and bones of the spine fuse together. The disease is

With this decision, eligible adults in the UK with hATTR amyloidosis can gain access to patisiran before the drug is granted marketing authorization by the European Commission (EC).

AstraZeneca licensed selumetinib from Array BioPharma in 2003. AstraZeneca and Merck have entered a co-development and co-commercialisation agreement for selumetinib in 2017. NF1 is an incurable genetic condition,

The phase 2 trial evaluated ridinilazole against Standard of Care vancomycin across 100 patients. By preserving the gut microbiome, the Summit drug was demonstrated to have brought down

The company’s announcement also included the issuance of $22m in shares upon conversion of debt into equity Participants included ARCH Venture Partners, the Wellcome Trust, Steven Paul M.D.,